๐Ÿ”Ž Trials Near Me

Home โ€บ Glioma

Glioma clinical trials recruiting in the U.S.

118 studies for Glioma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

RecruitingPhase 1/2
Ages 18 to 99 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07416188

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07326566

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

RecruitingPhase 1/2
12 Months โ€“ 21 Years ยท All sexes ยท Updated Sep 25, 2026 ยท NCT05099003

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT03896568

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RecruitingPhase 1/2
Up to age 25 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04094610

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

RecruitingEarly phase 1
Ages 1 to 21 ยท All sexes ยท Updated Sep 22, 2026 ยท NCT05555550

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

RecruitingPhase 2
12 Months โ€“ 39 Years ยท All sexes ยท Updated Sep 21, 2026 ยท NCT06838676

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 21, 2026 ยท NCT04977375

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Recruiting
Ages 15 to 120 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT07374692

Development of MRF for Characterization of Brain Tumors After Radiotherapy

RecruitingHealthy volunteers welcome
Ages 18 to 60 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT06101069

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

RecruitingPhase 1
Ages 5 to 18 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT06357377

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT04771806

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

RecruitingPhase 1
Ages 19 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT05698524

NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

RecruitingPhase 1
Ages 3 to 25 ยท All sexes ยท Updated Sep 9, 2026 ยท NCT07664176

Targeted Pediatric High-Grade Glioma Therapy

RecruitingObservational study
12 Months โ€“ 39 Years ยท All sexes ยท Updated Sep 8, 2026 ยท NCT05839379

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months โ€“ 22 Years ยท All sexes ยท Updated Sep 4, 2026 ยท NCT03911388

A Study of Mirdametinib in People With Central Nervous System Tumors

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 3, 2026 ยท NCT07539441

Assessing Brain Metabolism Using MRS With Deuterated Glucose

RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT06594315

Study of Olutasidenib and Temozolomide in HGG

RecruitingPhase 2
Ages 12 to 39 ยท All sexes ยท Updated Sep 1, 2026 ยท NCT06161974

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Aug 31, 2026 ยท NCT05489783

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT05303519

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

RecruitingPhase 1/2
Ages 15 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT05588141

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

RecruitingPhase 2
Ages 3 to 39 ยท All sexes ยท Updated Aug 24, 2026 ยท NCT05096481

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.